Adverse events and treatment interruption in tuberculosis patients with and without HIV co- infection

Breen, R. A. M.; Miller, R. F.; Gorsuch, T.; Smith, C. J.; Schwenk, A.; Holmes, W.; Ballinger, J.; Swaden, L.; Johnson, M. A.; Cropley, I.; Lipman, M. C. I.
September 2006
Thorax;Sep2006, Vol. 61 Issue 9, p791
Academic Journal
Background: Serious treatment associated adverse events are thought to occur more frequently in individuals with tuberculosis (TB) who are co-infected with HIV. A study was undertaken to assess the frequency of serious (grade Ill/IV) adverse events and interruption of anti-TB treatment in the era of effective antiretroviral therapy. Methods: The incidence of serious adverse events was retrospectively compared in 312 individuals treated for TB, 156 of whom were co-infected with HIV. Results: 111 HIV infected individuals (71%) received highly active antiretroviral therapy at the same time as anti-TB treatment. Serious adverse events were recorded in 40% HIV infected and 26% HIV uninfected individuals (p = 0.008). Peripheral neuropathy and persistent vomiting were more common in co-infected patients (p<0.001; p = 0.006), although all cause interruption of anti-TB treatment occurred with similar frequency in the two groups (13% in HIV infected patients and 15% in HIV uninfected patients; p = 0.74). In 85% of HIV infected patients and 87% of HIV uninfected individuals this was due to hepatotoxicity, which typically presented within 2 months of starting treatment. The median delay in restarting treatment was 4 weeks, so most individuals required full TB re-treatment. Conclusion: Despite a greater rate of serious (grade III/IV) adverse events among HIV infected individuals, discontinuation of anti-TB treatment occurred with a similar frequency in HIV infected and HIV uninfected individuals.


Related Articles

  • Issues in Correctional HIV Care: Treatment of Tuberculosis. Macher, Abe // American Jails;Jan/Feb2005, Vol. 18 Issue 6, p25 

    Discusses specific treatment considerations for patients with HIV-infection and tuberculosis (TB) in the U.S. Total number of TB cases in the country; Use of antiretroviral drugs in patients with concomitant TB; Association of all antiretroviral drugs with the potential for hepatotoxicity.

  • Tuberculosis and HIV Co-Infection: A Practical Therapeutic Approach. Breen, Ronan A. M.; Swaden, Leonie; Ballinger, Jayne; Lipman, Marc C. I. // Drugs;2006, Vol. 66 Issue 18, p2299 

    HIV and tuberculosis (TB) are leading global causes of mortality and morbidity, and yet effective treatment exists for both conditions. Rifamycin-based antituberculosis therapy can cure HIV-related TB and, where available, the introduction of highly active antiretroviral therapy (HAART) has...

  • Tuberculosis.  // Thorax;Dec2003 Supplement 3, Vol. 58, piii40 

    Antiretroviral therapy has had a major impact on HIV/TB co-infection. However drug interactions are common. The article sought to ascertain the success of HIV plus TB plus treatment regimens in the era of HAART, focusing on side effects and outcome. As part of Enhanced Tuberculosis Surveillance,...

  • Initial Response to Protease-Inhibitor-Based Antiretroviral Therapy among Children Less than 2 Years of Age in South Africa: Effect of Cotreatment for Tuberculosis. Reitz, Cordula; Coovadia, Ashraf; Ko, Stephen; Meyers, Tammy; Strehlau, Renate; Sherman, Gayle; Kuhn, Louise; Abrams, Elaine J. // Journal of Infectious Diseases;4/15/2010, Vol. 201 Issue 8, p1121 

    Background. South African guidelines recommend protease-inhibitor-based antiretroviral therapy (ART) with lopinavir-ritonavir for human immunodeficiency virus (HIV)-infected children <36 months of age.We investigated factors associated with viral suppression and mortality among young children...

  • Clinical response of newly diagnosed HIV seropositive & seronegative pulmonary tuberculosis patients with the RNTCP Short Course regimen in Pune, India. Tripathy, S.; Anand, A.; Inamdar, V.; Manoj, M. M.; Khillare, K. M.; Datye, A. S.; Iyer, R.; Kanoj, D. M.; Thakar, M.; Kale, V.; Pereira, M.; Risbud, A. R. // Indian Journal of Medical Research;May2011, Vol. 133 Issue 5, p521 

    Background & objectives: in the Revised National Tuberculosis Control Programme (RNTCP) in India prior to 2005, TB patients were offered standard DOTS regimens without knowledge of HIV status. Consequently such patients did not receive anti-retroviral therapy (ART) and the influence of...

  • Combined antiretroviral and anti-tuberculosis drug resistance following incarceration. Stott, K. E.; de Oliviera, T.; Lessells, R. J. // Southern African Journal of HIV Medicine;Sep2013, Vol. 14 Issue 3, p135 

    We describe a case of HIV/tuberculosis (TB) co-infection from KwaZulu-Natal, South Africa, characterised by drug resistance in both pathogens. The development of drug resistance was linked temporally to two periods of incarceration. This highlights the urgent need for improved integration of...

  • AIDS-Related Tuberculosis in Rio de Janeiro, Brazil. Pacheco, Antonio G.; Durovni, Betina; Cavalcante, Solange C.; Lauria, L. M.; Moore, Richard D.; Moulton, Lawrence H.; Chaisson, Richard E.; Golub, Jonathan E. // PLoS ONE;2008, Vol. 3 Issue 9, p1 

    Background: We studied the incidence of tuberculosis, AIDS, AIDS deaths and AIDS-TB co-infection at the population level in Rio de Janeiro, Brazil where universal and free access to combination antiretroviral therapy has been available since 1997. Methodology/Principal Findings: This was a...

  • Linking HIV-Infected TB Patients to Cotrimoxazole Prophylaxis and Antiretroviral Treatment in India. Raizada, Neeraj; Chauhan, Lakbir Singh; Babu, B. Sai; Thakur, Rahul; Khera, Ajay; Wares, D. Fraser; Sahu, Suvanand; Bachani, D.; Rewari, B. B.; Dewan, Puneet K. // PLoS ONE;2009, Vol. 4 Issue 6, p1 

    Background: HIV-infected persons suffering from tuberculosis experience high mortality. No programmatic studies from India have documented the delivery of mortality-reducing interventions, such as cotrimoxazole prophylactic treatment (CPT) and antiretroviral treatment (ART). To guide TB-HIV...

  • HIV Testing and Treatment Among Tuberculosis Patients -- Kenya, 2006-2009. Sitienei, J.; Kipruto, H.; Nganga, L.; Ackers, M.; Odhiambo, J.; Laserson, K.; Nakashima, A. K.; Modi, S. // MMWR: Morbidity & Mortality Weekly Report;11/26/2010, Vol. 59 Issue 46, p1514 

    The article discusses a report on HIV data from Kenya's tuberculosis (TB) surveillance system from 2006 to 2009. The Kenya Division of Leprosy, Tuberculosis and Lung Disease (DLTLD) added HIV testing and treatment to its TB surveillance program at the recommendation of the World Health...


Read the Article


Sign out of this library

Other Topics